Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 17

1.

Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105.

Hong H, Severin GW, Yang Y, Engle JW, Zhang Y, Barnhart TE, Liu G, Leigh BR, Nickles RJ, Cai W.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):138-48. doi: 10.1007/s00259-011-1930-x. Epub 2011 Sep 10.

2.

In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis.

Yang Y, Zhang Y, Hong H, Liu G, Leigh BR, Cai W.

Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):2066-76. doi: 10.1007/s00259-011-1886-x. Epub 2011 Aug 4.

3.

Molecular mechanisms and clinical applications of angiogenesis.

Carmeliet P, Jain RK.

Nature. 2011 May 19;473(7347):298-307. doi: 10.1038/nature10144. Review.

4.

Positron emission tomography imaging of CD105 expression during tumor angiogenesis.

Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, Leigh BR, Cai W.

Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1335-43. doi: 10.1007/s00259-011-1765-5. Epub 2011 Mar 4.

5.

Endoglin-targeted cancer therapy.

Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, Harada N, Uneda S, Tsujie T, Toi H, Tsai H, Haruta Y.

Curr Drug Deliv. 2011 Jan;8(1):135-43. Review.

6.

Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.

Abdollahi A, Folkman J.

Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28. doi: 10.1016/j.drup.2009.12.001. Epub 2010 Jan 12. Review.

PMID:
20061178
7.

Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.

Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, Tsai H, Seon BK.

Int J Cancer. 2008 May 15;122(10):2266-73. doi: 10.1002/ijc.23314.

8.

Arming antibodies: prospects and challenges for immunoconjugates.

Wu AM, Senter PD.

Nat Biotechnol. 2005 Sep;23(9):1137-46. Review.

PMID:
16151407
9.

Targeting of radio-isotopes for cancer therapy.

Milenic DE, Brechbiel MW.

Cancer Biol Ther. 2004 Apr;3(4):361-70. Epub 2004 Apr 3. Review.

PMID:
14976424
10.

Vascular targeting agents as cancer therapeutics.

Thorpe PE.

Clin Cancer Res. 2004 Jan 15;10(2):415-27. Review.

11.

Endoglin (CD105): a target for anti-angiogenetic cancer therapy.

Fonsatti E, Altomonte M, Arslan P, Maio M.

Curr Drug Targets. 2003 May;4(4):291-6. Review.

PMID:
12699349
12.

Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model.

Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M, Maio M.

Clin Cancer Res. 2000 May;6(5):2037-43.

13.

Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin.

Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R.

Eur J Cancer. 2000 Mar;36(5):675-81.

PMID:
10738134
14.
15.

Angiogenesis in cancer, vascular, rheumatoid and other disease.

Folkman J.

Nat Med. 1995 Jan;1(1):27-31. Review.

PMID:
7584949
16.

Transforming growth factor-beta.

Massagué J, Cheifetz S, Laiho M, Ralph DA, Weis FM, Zentella A.

Cancer Surv. 1992;12:81-103. Review.

PMID:
1638549
17.

Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells.

Cheifetz S, Bellón T, Calés C, Vera S, Bernabeu C, Massagué J, Letarte M.

J Biol Chem. 1992 Sep 25;267(27):19027-30.

Supplemental Content

Support Center